CompoundsActive IngredientsAxitinib CAS 319460-85-0

SKU: WGP-319460-85-0-1

Axitinib

CAS 319460-85-0

Molecular Formula: C22H18N4OS
Molecular Weight: 386.47
MOQ:1KG
Availability: On Order
Packaging: Regular packaging or customised

 

Contact us directly for more

Telegram Telegram Signal Signal Threema Threema
  • Description
  • Our Policy

Description

Axitinib CAS 319460-85-0 Product Information

Product Name: Axitinib
Synonyms: N-Methyl-2-({3-[(E)-2-(2-pyridinyl)vinyl]-1H-indazol-6-yl}sulfanyl)benzamide;Benzamide, N-methyl-2-[[3-[(E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-;UNII-C9LVQ0YUXG;;Inlyta;Benzamide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-;10mg;N-Methyl-2-({3-[(E)-2-(pyridin-2-yl)vinyl]-1H-indazol-6-yl}sulfanyl)benzamide;AG-013736 N-Methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide;Axtinib;AVERMECTINB;N-methyl-2-({3-[(E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide;
CAS NO: 319460-85-0
Molecular Weight: 386.47
Molecular Formula: C22H18N4OS
Boiling Point: 668.9±55.0 °C(Predicted)
Melting point: 213-215°C
Density: 1.4
Appearance: white to tan Powder
Purity: >98%
Storage: room temp
Storage: Keep in dark place,Inert atmosphere,Room temperature

What is axitinib

Axitinib is a pharmaceutical agent employed for the therapeutic management of various forms of cancer, particularly renal cell carcinoma, a kind of kidney cancer. Below are few essential aspects regarding axitinib:

1. Chemical Structure and Classification:

  • Axitinib is classified as a tyrosine kinase inhibitor (TKI). The chemical formula of the compound is C22H18N4OS, and its structure consists of many aromatic rings and a sulphur atom.
  • The user did not provide any text. It selectively targets and blocks tyrosine kinases, which are proteins that have a crucial function in the signalling pathways that control cell division, growth, and survival.

2. Mechanism of Action:

  • Axitinib functions by blocking the activity of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3. These receptors have a role in angiogenesis, the process of creating new blood vessels.
  • Axitinib inhibits the growth and multiplication of tumours by blocking VEGFRs, which lowers the blood supply to the tumours.

3. Therapeutic Application:

  • Axitinib is predominantly employed for the treatment of advanced renal cell carcinoma (RCC) in patients who have undergone one prior systemic therapy.
  • It is ingested through the mouth in the form of tablets.

4. Dosage and Administration:

  • The suggested initial dosage for axitinib is generally 5 mg administered twice day. Modifications to the dosage may be implemented depending on the patient’s ability to tolerate the treatment and their response to it.
  • The user did not provide any text. The medication should be administered at approximately 12-hour intervals, regardless of whether food is consumed or not.

5. adverse Effects:

  • Axitinib may cause hypertension (high blood pressure), diarrhoea, lethargy, decreased appetite, nausea, and weight loss as common adverse effects.
  • The user did not provide any text. Additional severe adverse effects may encompass haemorrhage, arterial or venous thrombotic events, gastrointestinal perforation, and thyroid dysfunction.
  • Close monitoring is necessary for patients receiving axitinib medication to detect and manage any potential adverse effects.

6. Drug Interactions:

  • Axitinib may interact with other drugs, especially those that impact the liver enzymes responsible for drug metabolism (such as CYP3A4 inhibitors or inducers).
  • The user did not provide any text. It is crucial to notify healthcare providers about all medications and supplements being consumed in order to prevent potential interactions.

7. Approval and Availability:

This medicine has received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its use in treating advanced renal cell carcinoma.

To summarise, axitinib is a crucial therapeutic choice for managing advanced renal cell carcinoma. It acts as a tyrosine kinase inhibitor, effectively obstructing angiogenesis and the growth of tumours. The administration and potential negative effects of this medication necessitate vigilant supervision by healthcare professionals.

Transit time You will normally receive your parcel within 7-15 working days after shipment (this may be delayed in special circumstances, such as Chinese New Year).
Receiving method Generally we will send the goods by courier or special line, of course, if the goods themselves in the local warehouse have goods, also support self-pickup, depending on the circumstances.
Overseas warehouse We have overseas warehouses in some European countries and Australia, such as Germany, Russia and Australia.
Delivery Method WGP will ship via courier companies such as DHL, FedEx, UPS, TNT or EMS.
About After Sales Within 7 days of your receipt of the goods if you find any problems with the goods (broken packaging, less hair, etc.) please feel free to contact our sales, we will help you deal with it in time.

You may also like…

Reviews

There are no reviews yet.

Be the first to review “Axitinib CAS 319460-85-0”

error: Alert: Content is protected !!